报名：首届全球骨科大会 | 参会须知 报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月22日， 惠泰医疗 发布了2024年年报。 # 财务与市场表现 骨未来 | 智汇骨 | 思宇MedTech 首届全球骨科大会 Global Orthopedics Conference 主办单位:骨未来、智汇骨、思宇MedTech 协办单位:中关村联新生物医药产业联盟 支持单位:北京中关村科学城创新发展有限公司 北京中关村创业大街科技服务有限公司 启迪之星 中关村科学城CGT产业孵化中心 中国 北京 2025年4月24日 心未来 | 思宇MedTech 24年实现营收 20.66亿 元（+25.2%）；归母净利润 6.73亿 元（+26.1%） ；扣非归母净利润6.43亿元 （+37.3%）。经计算，24年Q4实现营收5.41亿元（+23.9%）；归母净利润1.45亿元（+11.0%）；扣非归 母净利润1.35亿元（+24.69%）。25年Q1公司实现营收5.64亿元 (+23.9%)，归母净利润1.83亿元 (+30.7%)，扣非归母净利润1.81亿元 (+32.2%)。24 ...

Financial and Market Performance - In 2024, the company achieved revenue of 2.066 billion yuan (+25.2%) and a net profit attributable to shareholders of 673 million yuan (+26.1%), with a non-recurring net profit of 643 million yuan (+37.3%) [2] - For Q4 2024, the company reported revenue of 541 million yuan (+23.9%) and a net profit of 145 million yuan (+11.0%), with a non-recurring net profit of 135 million yuan (+24.69%) [2] - In Q1 2025, the company generated revenue of 564 million yuan (+23.9%) and a net profit of 183 million yuan (+30.7%), with a non-recurring net profit of 181 million yuan (+32.2%) [2] - The growth in profits for 2024 and Q1 2025 was driven by increased sales volume, enhanced product profitability, and cost control measures [2] Business Segments - In 2024, the electrophysiology business generated revenue of 440 million yuan (+19.7%), while the coronary access segment achieved 1.054 billion yuan (+33.3%), and peripheral intervention revenue was 351 million yuan (+37.1%) [2] - Non-vascular intervention revenue reached 39 million yuan, showing a significant increase of 135.1%, while OEM revenue was 165 million yuan, a decrease of 21.7% [2] - Domestic business overall achieved 1.769 billion yuan (+25.7%), while overseas business revenue was 280 million yuan (+19.6%) [2] Product and Market Expansion - In 2024, the company added over 200 new hospitals for electrophysiology products, covering more than 1,360 hospitals, and completed over 15,000 three-dimensional electrophysiology surgeries, a 50% increase year-on-year [3] - The company maintains a leading market share in the adjustable bend ten-electrode coronary sinus catheter, with an annual usage exceeding 100,000 units [3] - In 2025, the company plans to complete clinical follow-ups for PFA net basket consumables and the ICE project registration, while advancing clinical projects for abdominal aortic stents and coronary peripheral shock wave balloons [3] Profitability Metrics - The gross margin for 2024 was 72.3% (+1.1 percentage points year-on-year), and the net profit margin was 32.6% (+0.2 percentage points year-on-year) [3] - For Q4 2024, the gross margin was 71.3% (+0.3 percentage points year-on-year), while the net profit margin was 26.8% (-3.1 percentage points year-on-year) [3] - In Q1 2025, the gross margin improved to 73.1% (+2.4 percentage points year-on-year), and the net profit margin was 32.5% (+1.7 percentage points year-on-year) [3] Dividend Policy - The company plans to distribute a cash dividend of 17.50 yuan (including tax) for every 10 shares to all shareholders, which accounts for 25.24% of the net profit attributable to shareholders for 2024 [3] Company Overview - Shenzhen Huitai Medical Devices Co., Ltd. is a high-tech enterprise established in 2002, focusing on the research, development, production, and sales of electrophysiology and interventional medical devices [4] - The company is headquartered in Shenzhen and has developed a product line primarily centered on coronary access and cardiac electrophysiology medical devices, with a focus on peripheral vascular and non-vascular interventional medical devices [4] - Huitai Medical emphasizes research and innovation, holding numerous domestic and international medical device registrations and certifications, with products sold in various countries and regions worldwide [4]

上海微创心脉医疗科技(集团)股份有限公司的主营业务是主动脉及外周血管介入医疗器械的研发、生产 和销售。公司的主要产品是胸主动脉覆膜支架系统、腹主动脉覆膜支架系统、术中支架类、球囊类、支 架类。公司获评上海市政府质量金奖、科创板公司价值30强、首届"未来20·中国A股上市公司成长力年 度企业"；子公司鸿脉、蓝脉、拓脉获评"科技型中小企业"，蓝脉首次通过高新技术企业认定并获评"张 江年度新锐"企业；Castor分支型胸主动脉覆膜支架进入国家知识产权局《第二十五届中国专利金奖预 获奖项目》公示名录;静脉支架等入选《上海市"新优药械"产品目录》和《浦东新区创新药械产品推荐 目录》，另有5个项目获评浦东职工科技创新项目。总裁朱清入选"明珠领军人才"，刘梦钦、王金耀、 屠春霖、樊亚明入选"明珠工程师"。 最新一期业绩显示，2024年年报，公司实现营业收入12.06亿元，同比1.61%；净利润5.02亿元，同比 1.96%，销售毛利率73.01%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)48心脉医疗21.9121.912.90110.00亿行业平均 46.1548.384.77102.50亿行业中值29.1 ...

2025年2月11日，得益于第四季度业绩超预期，爱德华生命科学（NYSE：EW）股价在盘后交易中上涨。截至盘后，EW股价上涨 7% ，至每股 75.88美元 第四季度 爱德华生命科学 公司实现 利润3.856亿美元 ，合每股收益 65美分 ，销售额达 13.86亿美元 （合约 101.178亿人民币 ）。在销售额同比 增长 9.4% 的推动下，公司净利润增长 4.2% 。 剔除一次性项目后，调整后每股收益为 59美分 ，较华尔街预期高出4美分。此外，公司销售额也超出市场预期的 13.6亿美元 。 # 财 报 详情 第四季度销售额同比增长 9% ，达到 13.9亿美元 ，超出市场预期。所有产品线均呈现强劲增长态势。 经汇率调整后，第四季度经导管主动脉瓣置换术（TAVR）销售额实现 5% 的增长，按报告汇率计算增长率为 6% 。 经导管二尖瓣和三尖瓣治疗（TMTT）业务表现尤为突出，第四季度销售额同比增长 88% ，达到 1.05亿美元 ，成为推动公司业绩增长的重要引擎。 第四季度基本每股收益为 0.58美元 ，经调整后每股收益为 0.59美元 ，主要得益于强劲的销售业绩。 财务表现 临床进展 公司在第四季度公布 ...